Another Nail In The Coffin For The High Carb Diet
Anyone who reads my articles and ebooks knows I am not a fan of high carb diets, especially if it’s a low fat low protein diet combined with a high carbohydrate intake. Some interesting new research supports a lower carb intake.
OK, it’s done on mice, and early research, but interesting and another potential nail in the coffin of the high carb diet. Of course, a drug to block XBP1 (see article below) will be in development, when a low carb diet may work just as well -at least in some people. Interesting information and research to keep an eye on:
ScienceDaily (Jun. 13, 2008) — Researchers have discovered an unknown regulator of fat and cholesterol production in the liver of mice, a significant finding that could lead to new therapies for lowering unhealthy blood levels of cholesterol and fats.
The team led by scientists from the Harvard School of Public Health (HSPH) showed how this might work in an animal model, demonstrating that turning off the regulatory molecule — known as XBP1 — dramatically reduced blood levels of cholesterol and triglyceride fats. Importantly, there were no apparent adverse effects on the liver.
Therefore, “XBP1 may be an attractive drug target for treating dyslipidemias [excess fats in the blood],” said Laurie Glimcher, professor of immunology in the Department of Immunology and Infectious Diseases at HSPH. She is senior author of a new report in the journal Science. She said she and her colleagues are working with collaborators at the Broad Institute of MIT and Harvard to explore strategies for inhibiting XBP1 activity that could be applicable to humans.
“A key finding is that the liver in the mice lacking XBP1 seems to be perfectly normal, with minor effect on normal protein synthesis,” Glimcher added. “It is a very selective effect in lowering cholesterol and triglyceride production.”
The researchers discovered that XBP1, a transcription factor that governs gene expression, is activated by the ingestion of a high carbohydrate diet. XBP1 then turns on genes for enzymes that cause the liver to manufacture fat and fat-like substances, which are transported in the blood to fat tissue for storage. Excess amounts of these compounds — cholesterol and triglycerides — in the bloodstream can be dangerous, leading to heart disease and increased risk of strokes.
The discovery of XBP1′s role in manufacturing fats was a surprise to Glimcher and her co-workers, who include Ann-Hwee Lee, research scientist at HSPH, Erez Scapa, PhD, and David Cohen, MD, PhD. Lee is first author of the publication. Scapa and Cohen are affiliated with Harvard Medical School and Brigham and Women’s Hospital.
The molecule had been discovered by Glimcher two decades ago when she was searching for regulators of genes in the Major Histocompatiblity Complex, or MHC, a group of proteins that enables the immune system to distinguish between “self” and foreign substances in the body.
More recently, she and others characterized the function of XBP1 as a coordinator of an emergency response that cells use to survive when they are threatened by the stress of misfolded proteins. The survival strategy is known as the Unfolded Protein Response, or UPR. In addition, XBP1 is required for the normal development of the fetus, including the liver, and mice lacking XBP1 do not survive to birth.
So what is the role of XBP1 in the adult liver, the scientists wondered. Lee and colleagues developed a mouse model in which XBP1 functioned normally during fetal development but could be inactivated at will in the adult. To their surprise, the researchers found that knocking out XBP1 in adult rodents had no obvious abnormalities — nor was there any evidence of damage to the liver.
What they did observe, however, was a dramatic decrease of cholesterol, triglycerides and free fatty acids in the XBP1-knockout mice compared with normal controls. Moreover, the lack of XBP1 almost entirely eliminated the “bad” LDL cholesterol in the bloodstream. Concerned that the triglycerides might be accumulating in the liver instead — a condition in humans called “fatty liver” — the researchers found this was not the case, indicating that the manufacture of triglycerides in the liver was shut down.
When individuals eat excess carbohydrates, their bodies convert surplus carbohydrates into triglycerides to store them in fat tissue, which may be used as an energy source when food intake is limited. This lipid synthesis process occurs in the liver and is dynamically controlled depending on nutritional condition. XBP1, activated by a high-carbohydrate diet that strongly promotes lipid synthesis in the liver, induces several critical enzymes governing this process.
The Glimcher team concluded that XBP1 has a distinct role in generating lipids in the liver when stimulated by a high-carbohydrate diet and that this role is not connected in any way with its function as a regulator of the unfolded protein response. Because XBP1 acts in such a selective way on the liver’s lipid-making mechanism, the researchers are eager to determine whether drugs targeted to the molecule have a future in treating individuals with high blood levels of triglycerides and cholesterol.
Elevated levels of triglycerides and LDL cholesterol are key features of metabolic syndrome, which confers high risk of type 2 diabetes and atherosclerosis. The widely used drugs known as statins reduce blood cholesterol by inhibiting a key enzyme for its synthesis in the liver; they lower the risk of atherosclerosis. It appears that XBP1 controls the biosynthesis pathways for both triglycerides and cholesterol. The researchers hope that compounds that block the XBP1 pathway could lower both triglycerides and cholesterol and thereby help prevent diabetes and atherosclerosis.
“We don’t yet know whether blocking the XBP1 pathway will be better than the statins, which are very good drugs but have side effects like all drugs do,” Glimcher said. “But it is a different pathway.”
This study was supported by the National Institutes of Health and an Ellison Medical Foundation grant.